Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view.
Prasad
Vikas
V
Department of Nuclear Medicine, Center for PET/CT, Zentralklinik Bad Berka, Germany.
Fetscher
S
S
Baum
Richard P
RP
D018849:Controlled Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D066298:In Vitro Techniques; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000503:physiopathology; D009683:Nuclear Medicine; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide / Q000187:drug effects / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000187:drug effects* / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology*
D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D017481:Receptors, Somatostatin; D013004:Somatostatin